RCS - Diaceutics PLC - Investor Presentation

DiaceuticsAnnouncement

21/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220221:nRSU1842Ca&default-theme=true

RNS Number : 1842C  Diaceutics PLC  21 February 2022

21 February 2022

Diaceutics PLC

("Diaceutics" or the "Group" or the "Company")

Investor Presentation

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company,
announces that CEO Peter Keeling and incoming CFO Nick Roberts will provide a
live presentation relating to the Company's audited results for the year
ended 31 December 2021 via the Investor Meet Company platform on 23 March
2022 at 1pm.

 

The presentation is open to all existing and potential shareholders and
registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor
(https://www.investormeetcompany.com/diaceutics-plc/register-investor) .

 

Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 9am the day before the meeting or at any time during the live
presentation.

 

Investors who already follow Diaceutics on the Investor Meet Company platform
will automatically be invited.

 

Enquiries:

 Diaceutics PLC                                         Via Alma PR

 Peter Keeling, Chief Executive Officer

                                                       Tel: +44 (0)20 7710 7600

 Stifel Nicolaus Europe Limited (Nomad & Broker)

 Ben Maddison

 Stewart Wallace                                       Tel: +44(0)20 3405 0205

 Nick Adams                                            diaceutics@almapr.co.uk

 Alma PR

 Caroline Forde

 Kieran Breheny

 Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQVLFFLLLFBBL